Constitutional Challenge Threatens DEA Marijuana Rescheduling Process

Constitutional Argument Targets DEA Authority

The challenge asserts that rescheduling cannabis—a decision with sweeping economic and criminal-justice implications—exceeds DEA's administrative authority and belongs to Congress. According to the filing, the nondelegation doctrine prohibits agencies from making policy decisions of this magnitude without explicit congressional direction.

The argument turns on the Supreme Court's recent revival of nondelegation review in cases like West Virginia v. EPA (2022). That decision established the "major questions doctrine." It held that agencies can't claim transformative regulatory power based on ambiguous statutory language.

Cannabis rescheduling affects interstate commerce worth an estimated $30 billion annually, federal tax treatment under Section 280E, and criminal penalties for millions of Americans. These stakes require legislative action, the filing contends, not administrative rulemaking.

Timing Threatens Final Rule Publication

The constitutional challenge arrives as DEA nears completion of its rescheduling review, with a final rule expected by August 2026. DEA published its Notice of Proposed Rulemaking in May 2024, opened a public comment period that drew over 43,000 submissions, and held administrative hearings in December 2025.

A federal court could bar the agency from publishing the final rule until the constitutional question gets resolved, if it grants preliminary relief. That timeline could stretch into 2027 or beyond, depending on appellate review.

DEA hasn't yet responded to the filing. The agency's rescheduling process began in August 2023 following a Health and Human Services Department recommendation that cannabis meets the criteria for Schedule III classification.

Industry and Advocacy Groups Watch Closely

Multi-state operators and cannabis trade groups have invested heavily in the expectation that Schedule III reclassification will eliminate the Section 280E tax burden. That IRS provision prohibits businesses trafficking in Schedule I or II substances from deducting ordinary expenses. It costs the industry an estimated $1.8 billion annually in excess federal taxes.

Key industry concerns include:

• Banking access—Schedule III status may ease federal enforcement risk for financial institutions
• Interstate commerce—rescheduling doesn't legalize cannabis but removes certain federal barriers
• State-legal markets—35 states with adult-use or medical programs operate in tension with federal Schedule I classification

Advocacy organizations including the National Organization for the Reform of Marijuana Laws have argued that full descheduling, not rescheduling, is the appropriate policy outcome. This constitutional challenge doesn't advocate for descheduling. Instead, it seeks to block administrative rescheduling altogether.

What Comes Next

The filing will proceed to federal district court, where the plaintiff must demonstrate standing and likelihood of success on the merits to obtain preliminary injunctive relief. Standing requirements—proof of concrete injury—may prove the first hurdle. Courts have historically been reluctant to grant pre-enforcement review of agency rules.

If the challenge survives initial procedural review, briefing on the constitutional question could take four to six months. A ruling against DEA would almost certainly be appealed to a circuit court and potentially the Supreme Court, given the precedential implications for administrative law.

For background on the DEA rescheduling timeline and HHS recommendation, see the CannIntel topic hub on DEA rescheduling.